Myriad Genetics (MYGN) said Monday that it "strongly disagrees" with UnitedHealthcare's decision to restrict coverage access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under the commercial and individual exchange benefit plans.
The updated policy, which takes effect on Jan. 1, is based on the rationale that there is insufficient evidence of efficacy to support coverage of GeneSight, according to the company.
Myriad said it is working with UnitedHealthcare to discuss the clinical evidence for GeneSight and get continued coverage access for the test.
UnitedHealthcare did not immediately respond to MT Newswires' request for comment.
Myriad Genetics' shares were down more than 3% in recent trading.
Price: 17.39, Change: -0.60, Percent Change: -3.34
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。